Exclusive Summary

• Targets the multi-billion dollar Trastuzumab Deruxtecan (Enhertu) market with high-barrier DAR 8 ADC technology, addressing the expanded HER2-low and HER2+ oncology indications.
• The proprietary DAR 8 technology represents a high barrier to entry with limited global competition, offering superior stability and clinical differentiation compared to traditional ADCs.
• The 'NewCo' partnership model offers international partners a flexible structure for co-development and risk-sharing, accelerating the path to market entry for this high-value asset.

Asset Materials

Contact Us for Full Materials